
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is showing strong financial performance with 1Q26 net revenue of €6.4M and a projected 1Q26 and 2Q26 net revenue of $6M and $7.5M respectively. The company is executing well in a noisy reimbursement environment, showing 15% y/y decrease in op ex, and expects to achieve breakeven at or below €150M in revenue. With positive data points and a growing salesforce, Nyxoah has the potential to become a high-growth asset, but may need to bolster its balance sheet.
Bears say
Nyxoah is a medical technology company focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea, with its lead solution being the Genio system. The company has shown strong revenue growth in Q1 2021, but its gross margin and operating expenses were below analyst estimates. The completion of the ACCCESS study in late June 2026/early July 2026 could be a key catalyst, but label expansion is not expected until early-2027. The company has been in operation since 2009.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares